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It has not been established if dietary factors or nutri-
tional supplements impact on the incidence of cancer
in high-risk women. We randomised 1135 women with
a BRCA1 mutation to 250 micrograms daily of elemen-
tal selenium as sodium selenite, or to placebo, in a
double-blind trial. After a median follow-up period of
35 months (range 6 to 62 months), there were 60 inci-
dent cases of cancer diagnosed in the selenium-supple-
mented group, versus 45 cases in the placebo group
(hazard ratio 1.4; 95% CI: 0.9 to 2.0). Selenium supple-
mentation was not associated with a reduction in the
risk of primary breast cancer (hazard ratio 1.3; 95% CI:
0.7 to 2.5), of contralateral breast cancer (hazard ratio
1.5; 95% CI: 0.7 to 3.2), or of ovarian cancer (hazard
ratio 1.3; 95% CI: 0.6 to 2.7). The results of this study
do not support the recommendation that selenium
supplementation should be offered to BRCA1 carriers
for chemoprevention.
Part II Adnexectomy, genotypes and selenium level as
markers of the risk of cancer
In these part we conducted a nested case-control
s t u d yo f6 8w o m e nw i t hb r e a s tc a n c e ra n d1 7w o m e n
with ovarian cancer and 170 controls matched 1 to 2.
Cases and controls were matched for age at enrolment,
past history of breast cancer, oophorectomy and
whether they received selenium supplement or placebo
during cancer chemoprevention trial. Combinations of
clinical status, genotypes and selenium levels strongly
associated with extremely low risk of cancer have been
identified.
The strongest associations have been found for GPX4
variants:
a. all nTT and Se level 60-80µg/l – OR 0.32, p: 0.0009
b. all TT and Se level >80µg/l – OR 0.10, p: 0.047
c. for carriers without adnexectomy and with TT var-
iant, Se level >80µg/l – OR 0.038, p: 0.014.
Author details
1Department of Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Szczecin, Poland.
2Prophylactic and
Epidemiology Center, Poznan, Poland.
3Institute of Occupational Medicine,
Lodz, Poland.
4Regional Oncology Hospital, Swidnica, Poland.
5Regional
Oncology Hospital, Opole, Poland.
6Center of Oncology of Lublin Region,
Lublin, Poland.
7Regional Oncology Center, Krakow, Poland.
8Womens
College Research Institute and Dalla Lana School of Public Health, University
of Toronto, Canada.
Published: 1 June 2011
doi:10.1186/1897-4287-9-S2-A5
Cite this article as: Lubinski et al.: Selenium and the risk of cancer in
BRCA1 carriers. Hereditary Cancer in Clinical Practice 2011 9(Suppl 2):A5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Department of Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Szczecin, Poland
Full list of author information is available at the end of the article
Lubinski et al. Hereditary Cancer in Clinical Practice 2011, 9(Suppl 2):A5
http://www.hccpjournal.com/content/9/S2/A5
© 2011 Lubinski et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.